Publications by authors named "Rees Ahmed"
Nephrol Dial Transplant
August 2024
Article Synopsis
- Clinical trials have shown that SGLT2 inhibitors like dapagliflozin benefit adults with diabetic and chronic kidney diseases, but their effects on younger patients, especially those with Alport syndrome, remain unclear.
- The DOUBLE PRO-TECT Alport trial will involve participants aged 10 to 39 with a confirmed diagnosis of Alport syndrome and elevated albumin levels, testing the drug's safety and efficacy over 48 weeks compared to a placebo.
- The study aims to measure changes in urinary albumin-to-creatinine ratio (UACR) and kidney function to determine if these inhibitors can help protect against kidney failure in young patients.
